Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome
Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanism...
Saved in:
Main Authors: | Kira A Cozzolino, Lynn Sanford, Samuel Hunter, Kayla Molison, Benjamin Erickson, Meaghan CS Courvan, Taylor Jones, Deepa Ajit, Matthew D Galbraith, Joaquín M Espinosa, David Bentley, Mary Ann Allen, Robin D Dowell, Dylan J Taatjes |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2025-02-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/100197 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01) -
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays
by: Sandra Schwarzlose-Schwarck, et al.
Published: (2025-02-01) -
Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01) -
The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)